Search clinical trials for: Liraglutide, Empagliflozin and Linagliptin

Total 474609 results

Sichuan Haisco Pharmaceutical Group Co., Ltd

Completed

HSK7653 Metformin Add-on Study in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

China
Alexandria University

Completed

Empagliflozin as a Novel Therapy in Refractory Ascites

Ascites Hepatic

Egypt
Novo Nordisk A/S

Withdrawn

Research Study to Compare Semaglutide Tablets With Empagliflozin Tablets Taken Once Daily in People With Type 2 Diabetes and Obesity (PIONEER START)

Diabetes Mellitus, Type 2
RWTH Aachen University
Boehringer Ingelheim

Terminated

EMPA Acute Heart Failure

Diabetes Mellitus, Type 2 | Acute Heart Failure

Germany
McGill University

Completed

Low Dose Empagliflozin in Adults With Type 1 Diabetes on Closed Loop Insulin System (CL-LoDE)

Type 1 Diabetes

Canada
Caroline M Kistorp
Rigshospitalet, Denmark; Herlev and Gentofte Hospital; Danish Heart Foundation

Completed

SGLT-2 Inhibitor and Myocardial Perfusion, Function and Metabolism in T2 DM Patients at High Cardiovascular Risk (SIMPLE)

Type2 Diabetes Mellitus

Denmark
Ananda Basu, MD
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); DexCom... and other collaborators

Completed

SGLT2 Inhibitor Adjunctive Therapy to Closed Loop Control in Type 1 Diabetes Mellitus (CiQ-SGLT2)

Type 1 Diabetes

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors

Diabetes Mellitus, Type 2

United Kingdom
National Institute on Aging (NIA)

Completed

Sodium-glucose Co Transporter 2 (sGLT2) Inhibitor and Endogenous Ketone Production

Physiological Effects of Drugs | Hypoglycemic Agents | Empaglifozin | Sodium-Glucose Transporter 2 Inhibitors

United States
EMS

Withdrawn

Efficacy and Safety of Lima Association in the Control of Type II Diabetes Mellitus.

Type2 Diabetes Mellitus
Chungbuk National University Hospital

Active, not recruiting

Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy (LUCID)

Diabetes Mellitus, Type 2
Chungbuk National University Hospital

Completed

Head-to-head Comparison of Empagliflozin and Dapagliflozin

Type2 Diabetes

Korea, Republic of
Novo Nordisk A/S

Completed

Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus (PIONEER 2)

Diabetes Mellitus, Type 2 | Diabetes

United States, Croatia, Italy, Poland, Russian Federation, Spain, Greece, Serbia, Thailand, Brazil, Hungary, Argentina
Boehringer Ingelheim
Eli Lilly and Company

Completed

A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure

Heart Failure

United States, Denmark, Canada, Belgium, China, Italy, Germany, Spain, Netherlands, Hungary, Japan, Norway, Poland, Sweden, Czechia
Boehringer Ingelheim

Terminated

Real-world Study Comparing the Adherence and Effectiveness of Linagliptin vs. Acarbose

Diabetes Mellitus, Type 2

China
Samuel Lunenfeld Research Institute, Mount Sinai...
McGill University Health Centre/Research Institute of the McGill University...

Completed

Effect of SGLT2i in Conjunction With the Artificial Pancreas on Improving the Glycemia in T1DM in the Outpatient Setting (CLASS17)

Type1 Diabetes Mellitus

Canada
Boehringer Ingelheim
Eli Lilly and Company

Completed

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

Heart Failure

United States, Spain, Korea, Republic of, China, Germany, Belgium, Australia, Singapore, Canada, Italy, Argentina, Hungary, Czechia, Poland, Netherlands, Japan, United Kingdom, Mexico, Romania, Brazil, India, South Africa, Colombia
Boehringer Ingelheim

Withdrawn

Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas

Cardiovascular Diseases | Diabetes Mellitus, Type 2

United States
Medical University of Graz
Medical University of Vienna; Johannes Kepler University of Linz; Paracelsus... and other collaborators

Completed

Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction (EMMY)

Acute Myocardial Infarction

Austria
Getz Pharma

Completed

Comparison of Empaglifozin and Vildagliptin in Type 2 Diabetes Mellitus

Type 2 Diabetes

Pakistan
Sadat City University
Beni-Suef University

Completed

Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?

Diabete Type 2

Egypt
Sanofi

Completed

Comparison of Pharmacodynamic Effects of Sotagliflozin and Empagliflozin in T2DM Patients With Mild to Moderate Hypertension

Diabetes Mellitus

Germany
National University of Malaysia

Completed

Linagliptin Response to OGTT in Prediabetes and Type 2 Diabetes Mellitus

PreDiabetes | Type 2 Diabetes

Malaysia
Kasr El Aini Hospital

Completed

Empagliflozin in Patients With Glomerulonephritis

Proteinuria | Glomerulonephritis

Egypt
Boehringer Ingelheim

Completed

Post-authorization Safety Study in Type 2 Diabetic Patients in Saudi Arabia Treated With Empagliflozin to Assess the Incidence of Ketoacidosis, Severe Complications of Urinary Tract Infection, Volume Depletion, and Dehydration

Diabetes Mellitus, Type 2

Saudi Arabia
Mutah University

Completed

Pharmacokinetics and Bioequivalence of Two Empagliflozin, With Evaluation in Healthy Jordanian Subjects Under Fasting and Fed Conditions

Pharmacokinetic Parameters

Jordan
Boehringer Ingelheim
Eli Lilly and Company

Completed

Long Term Daily Use of JARDIANCE® Tablets in Japanese Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Japan
Boehringer Ingelheim

Completed

A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists

Diabetes Mellitus, Type 2

Germany
Boehringer Ingelheim

Completed

A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Korea, Republic of, Finland, Spain, Denmark, Germany, Israel, Japan, Norway, Sweden, Taiwan, United Kingdom
Alexandria University
Eva Pharma

Active, not recruiting

Anti-diabetic Drugs and Fatty Liver Management

Diabetes Mellitus, Type 2 | Fatty Liver, Nonalcoholic

Egypt
National Medical Research Center for Cardiology...
Ministry of Health of the Russian Federation

Completed

Effects of Empagliflozin on Exercise Capacity and Left Ventricular Diastolic Function in Patients With Heart Failure With Preserved Ejection Fraction and Type-2 Diabetes Mellitus

Diabetes Mellitus, Type 2 | Heart Failure, Diastolic

Russian Federation
University Hospital, Basel, Switzerland

Completed

Effects of the SGLT2-inhibitor Empagliflozin on Patients With Chronic SIADH - the SANDx Study (SANDx)

Hyponatremia | SIAD - Syndrome of Inappropriate Antidiuresis

Switzerland
Saint Luke's Health System

Completed

Empagliflozin Impact on Hemodynamics in Patients With Heart Failure (EMBRACE-HF)

Heart Failure

United States
Genuine Research Center, Egypt
Hikma Pharma

Completed

Bioequivalence Study of Empagliflozin & Metformin HCL From Empagliform 12.5/1000 mg F.C.T (Hikma Pharma, Egypt) and Synjardy 12.5/1000 mg F.C.T (Boehringer Ingelheim International GmbH, Germany)

Healthy

Egypt
Centro Universitario de Ciencias de la Salud, Mexico

Active, not recruiting

Acute Effect of Empagliflozin vs Dapagliflozin Over Pulse Wave Velocity in Type Two Diabetes

Diabetes Mellitus Type 2 Without Complication

Mexico
Handok Inc.

Completed

Pharmacokinetic Drug Interaction Between Teneligliptin and Empagliflozin

Type 2 Diabetes Mellitus

Korea, Republic of
Amsterdam UMC, location VUmc

Withdrawn

REGROUP: Renohemodynamic Effects empaGliflozin in vaRiOUs Populations (REGROUP)

Diabetes Mellitus, Type 2 | Chronic Kidney Diseases
Amsterdam UMC, location VUmc

Completed

Renohemodynamic Effects of Combined empagliflOzin and LosARtan (RECOLAR)

Diabetes Mellitus, Type 2 | Diabetic Kidney Disease

Netherlands
Roswell Park Cancer Institute

Completed

Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Clear Cell Adenocarcinoma | Ovarian Mucinous Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma | Fallopian Tube Endometrioid Adenocarcinoma and other conditions

United States
Korea University Anam Hospital

Completed

The Pharmacokinetics, Safety and Tolerability of IN-C009 in Healthy Subjects

Diabetes Mellitus

Korea, Republic of
Research Institute for Complex Problems of Cardiovascular...

Completed

Safety and Efficacy of Empagliflozin for Patients With Diabetes Mellitus and Planned Percutaneous Coronary Interventions (SAFARY)

Coronary Artery Disease | Diabetes Mellitus | Percutaneous Coronary Intervention
University of Pisa

Completed

Effects of Empagliflozin on Endogenous Glucose Production in End Stage Renal Disease(ESRD).

End Stage Renal Disease

Italy
Mario Negri Institute for Pharmacological Research
Boehringer Ingelheim

Withdrawn

SGLT2 Inhibitors in Glomerular Hyperfiltration (EMPATHY)

Obesity | Non-diabetic Chronic Kidney Disease
Chong Kun Dang Pharmaceutical

Completed

Evaluate the Drug-drugs Interaction Between Lobeglitazone 0.5mg and Empagliflozin 25mg

Type 2 Diabetes Mellitus

Korea, Republic of
Christian Schulze
Boehringer Ingelheim; Zentrum für Klinische Studien Jena

Completed

Effects of Empagliflozin on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF)

Acute Decompensated Heart Failure

Germany
Boehringer Ingelheim

Completed

A Study Using Swedish Registries to Find Out How Many People With Type 2 Diabetes Had Cardiovascular Disease and Started Treatment With Empagliflozin Between 2015 and 2017

Type 2 Diabetes Mellitus

Sweden
University of Dundee
British Heart Foundation

Completed

SGLT2 Inhibition in Combination With Diuretics in Heart Failure (RECEDE-CHF)

Heart Failure | Type 2 Diabetes Mellitus

United Kingdom
Samuel Lunenfeld Research Institute, Mount Sinai...
McGill University Health Centre/Research Institute of the McGill University... and other collaborators

Completed

Alleviating Carbohydrate-Counting Burden in T1DM Using Artificial Pancreas and Empagliflozin (CLASS15)

Type1diabetes

Canada
Boehringer Ingelheim
Eli Lilly and Company

Completed

A Study That Looks at the Function of the Heart in Patients With Heart Failure Who Take Empagliflozin

Heart Failure

United Kingdom
University of Miami

Withdrawn

Effects of DPP4 Inhibition on COVID-19

Coronavirus Infection | Type 2 Diabetes

United States

Search clinical trials for: Liraglutide, Empagliflozin and Linagliptin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Switzerland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations